Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Michigan Rx Rebate Program Decision Should Be Left To HHS, DoJ Tells Court

Executive Summary

HHS' approval of the Michigan Medicaid supplemental rebate program should be given deference in the Washington, D.C. federal court's review of the program, the Department of Justice said during oral arguments Aug. 28

You may also be interested in...



PhRMA v. HHS

D.C. federal court will hear additional arguments on the Pharmaceutical Research & Manufacturers of America's challenge of HHS' approval of the Michigan Medicaid supplemental rebate program Jan. 24. The court wants information on the effect the non-Medicaid aspects of the program will have on Medicaid beneficiaries. During oral arguments Jan. 6, the Department of Justice said the court should defer to HHS' approval (1"The Pink Sheet" Sept. 2, p. 6)...

PhRMA v. HHS

D.C. federal court will hear additional arguments on the Pharmaceutical Research & Manufacturers of America's challenge of HHS' approval of the Michigan Medicaid supplemental rebate program Jan. 24. The court wants information on the effect the non-Medicaid aspects of the program will have on Medicaid beneficiaries. During oral arguments Jan. 6, the Department of Justice said the court should defer to HHS' approval (1"The Pink Sheet" Sept. 2, p. 6)...

Michigan Rx Rebate Program Upheld In State Court; Federal Suit Pending

Michigan Medicaid's statutory authority to collect supplemental rebates has been upheld by the Michigan Court of Appeals

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS040415

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel